Guido Oelkers

Chairman & CEO

C-suiteM

FI·FIN-FSA

Swedish Orphan Biovitrum AB (publ)Swedish Orphan Biovitrum AB (publ)

Cumul. flow

0

Total declarations

0

Companies

—

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

Browse the complete record of transactions filed by Guido Oelkers, Chairman & CEO. Officer active across 2 companies, notably Swedish Orphan Biovitrum AB (publ). Aggregated, 3 reports have been logged. The latest transaction was disclosed on 31 October 2025 — Purchase. Regulator: FIN-FSA. The full history is accessible without signup.

Declarations3 total

Executives●PurchaseSSwedish Orphan Biovitrum AB (publ)36FIN-FSA

G

Guido OelkersVerkställande direktör (VD)

€2m80,000 shares@ €19.04750.0010% mcap41.3% of flow

Aktie

FI:A003T241-1·31 Oct 2025

Ideal exit: 28 Jul 2026 (T+270)

FIN-FSA ↗

Executives●PurchaseSSwedish Orphan Biovitrum AB (publ)29FIN-FSA

G

Guido OelkersVerkställande direktör (VD)

€2m80,000 shares@ €19.03920.0010% mcap41.3% of flow

Aktie

FI:A003T155-1·28 Oct 2025

Ideal exit: 25 Jul 2026 (T+270)

FIN-FSA ↗

Executives●PurchaseSSwedish Orphan Biovitrum AB (publ)27FIN-FSA

G

Guido OelkersVerkställande direktör (VD)

€640,57533,622 shares@ €19.05230.0004% mcap17.4% of flow

Aktie

FI:A003T122-1·27 Oct 2025

Ideal exit: 24 Jul 2026 (T+270)

FIN-FSA ↗

3 of 3 declarations

About Guido Oelkers

Guido Oelkers is the CEO of Swedish Orphan Biovitrum AB (publ). He is responsible for managing the company's operations, which specializes in orphan drugs. His role is essential for achieving the company's strategic objectives.